News
J&J says 2026 sales could top $100 billion
J&J says its sales should top $100 billion this year, as it pushes its oncology business towards a target of $50 billion by the end of the decade.
News
11 high-impact drugs to look out for in 2026
Medicines for obesity, diabetes, rare diseases, cancer, and women's health feature among Clarivate's annual round-up of 11 Drugs to Watch this year.
Oncology
Astellas’ banner year and focused R&D strategy, with Adam Pe...
At JPM2026, Astellas' chief strategy officer Adam Pearson walked pharmaphorum through the company’s four-pillared R&D strategy.
News
ImmunityBio rises as route opens to broader Anktiva label
Shares in ImmunityBio shot up after it agreed a path with the FDA that should allow it to refile for wider use of its bladder cancer drug Anktiva.
News
Data builds behind Moderna's skin cancer vaccine
Five-year results with Moderna/MSD's melanoma jab show a 49% reduction in disease progression or death, boding well for phase 3 data later this year.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
